Sobi

Sobi's journey began with roots in brewing in the 1930s, as a subsidiary of Kärnbolaget Aktiebolag Biokemisk Industri. This unlikely start involved exploring the potential of residual biological material. The 1940s, shaped by World War II, saw the company commissioned by the Swedish Armed Forces to manufacture freeze-dried blood plasma, leveraging its expertise in drying sensitive biological materials. Post-war, inspired by American researchers, the company ventured into blood plasma fractionation. The 1950s marked international expansion and a name change to Kabi®. Collaborations with Swedish researchers during this time led to the development of blood-clotting factors, laying the groundwork for future innovations. The 1960s were a period of transformative projects, including the pioneering production of growth hormones using DNA technology, while plasma fractionation became a core competence, offering hope to individuals with haemophilia.

Biovitrum® was spun out of Pharmacia in 2001, with a strategic focus on small molecular drugs in metabolic diseases and protein therapeutics. A pivotal moment came in 2006 with its stock exchange listing, which facilitated collaborations that led to breakthrough medicines like Alprolix® and Elocta®, significantly advancing haemophilia care globally. In 2010, a visionary acquisition led to the formation of Sobi, Swedish Orphan Biovitrum AB (publ), uniting the strengths of Swedish Orphan and Biovitrum. This merger combined Swedish Orphan's pan-European presence and diverse portfolio of orphan drugs with Biovitrum's expertise in product development, manufacturing, and a strong haemophilia franchise. Today, Sobi is an international biopharmaceutical company dedicated to transforming the lives of people with rare and debilitating diseases, providing access to innovative treatments in haematology, immunology, and specialty care. The company has a global presence, operating in around 30 countries and delivering medicines to patients in over 70 countries. In September 2024, Sobi moved its global headquarters to Hagastaden, Stockholm, Sweden, positioning itself in an international hub close to leading research institutions and Sweden's largest hospital to foster collaboration and innovation in life sciences.